Low-molecular-weight heparins during pregnancy

Canadian Family Physician

Volumn 51, Issue FEB., 2005, Pages 199-201

  Many, Ariel ^a   Koren, Gideon ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CERTOPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BIOEQUIVALENCE; BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDICATION; DRUG MILK LEVEL; DRUG PENETRATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; LUNG EMBOLISM; OSTEOPOROSIS; PLACENTA; PLACENTA PERFUSION; PREGNANCY; SKIN IRRITATION; TERATOGENICITY; THROMBOCYTOPENIA;

ANTICOAGULANTS; DALTEPARIN; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PULMONARY EMBOLISM;

EID: 14044257208     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. US Food and Drug Administration. FDA Med Watch. Rockville, Md: Food and Drug Administration; 2002. Available at: http://www.fda.gov/medwat. Accessed 2004 September 1.
2. Rai R, Cohen H, Dave M, Regan L. Controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997;314(7076):253-7.
3. Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. BMJ 2001;322:329-33.
4. Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, von Blomberg BME, Jakobs, C, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-8.
5. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of the genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340:9-13.
6. Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000;343:1015-8.
7. Many A, Elad R, Yaron Y, Eldor A, Lessing JB, Kupferminc MJ, Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. Obstet Gynecol 2002;99:684-7.
8. Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004;103:3695-9.
9. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002;87(2):182-6.
10. Carlin AJ, Farquharson RG, Quenby SM, Topping J, Fraser WD. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod 2004;19(5):1211-4.
11. Boskovic B, Koren G. Placental transfer of drugs. In: Yaffe J, Aranda JU, editors. Neonatal and pediatric pharmacology. Philadelphia, Pa: Lippincot Williams and Wilkins; 2005. p. 136.
12. Dimitrakakis C, Papageorgiou P, Papageorgiou I, Antzaklis A, Sakarelou N, Michalas S. Absence of transplacental passage of the low molecular weight heparin enoxaparin. Haemostasis 2000;30:243-8.
13. Richter C, Sitzmann J, Lang P, Weitzel H, Huch A, Huch R. Excretion of low molecular weight heparin in human milk. Br J Clin Pharmacol 2001;52(6):708-10.